Performance Characteristics
Detection Limit : PG I≤2.0 ng/mL , PG II≤ 1.0 ng/mL;
Linear Range:
PG I: 2.0-200.0 ng/mL, PG II: 1.0-100.0 ng/mL;
Linear coefficient coefficient R ≥ 0.990;
Kunyatsojeka: mukati mebatch CV iri ≤ 15%;pakati pezvikwata CV iri ≤ 20%;
Kurongeka: kutsauka kwehukama kwemhedzisiro yekuyera haipfuure ±15% apo yakamisikidzwa accuracy calibrator inoedzwa.
1. Chengeta detector buffer pa2～30℃.Iyo buffer yakagadzikana kusvika kumwedzi gumi nemasere.
2. Chengetedza Aehealth Ferritin Rapid Quantitative test cassette pa2～30℃, sherufu yeupenyu inokwana mwedzi gumi nemisere.
3. Test cassette inofanira kushandiswa mukati meawa imwe mushure mekuvhura paki.
Pepsinogen iprotease precursor yakavanzwa negastric mucosa uye inogona kukamurwa kuita maviri madiki: PG I uye PG II.PG I inovanzwa nemasero makuru e fundus glands uye cervical mucus cells, uye PG II inovanzwa ne fundus glands, pyloric glands, uye Brunner glands.Mazhinji eiyo synthesized PG inopinda mugastric cavity uye inogadziriswa pepsin pasi pechiito chegastric acid.Kazhinji, inenge 1% yePG inogona kupinda mukutenderera kweropa kuburikidza negastric mucosa, uye kuiswa kwePG muropa kunoratidza kuvharwa kwayo.PG I chiratidzo chekushanda kwegastric oxyntic gland masero.Kuwedzera gastric acid secretion kunowedzera PG I, kunoderedza secretion kana kuderedza gastric mucosal gland atrophy;PG II ine kuwirirana kukuru negastric fundus mucosal maronda (achienzaniswa negastric antral mucosa).Yakakwirira yakabatana ne fundus gland atrophy, gastric epithelial metaplasia kana pseudopyloric gland metaplasia, uye dysplasia;mukuita kwe fundus gland mucosal atrophy, nhamba yemasero makuru ekuvhara PG I inoderera uye nhamba yemasero epiloric gland inowedzera, zvichiita kuti PG I I / PG II chiyero inoderera.Naizvozvo, chiyero chePG I/PG II chinogona kushandiswa sechiratidzo chegastric fundic gland mucosal atrophy.